The news coming out of Berlin the last few weeks kind of makes you wonder how much longer a severely emaciated Biotronik can persist. The fact that the SCS device is in limbo must have sent shockwaves through the HQ ranks because the numbers of exits have increased dramatically, including the Head of Health Services who had only been in the role less than 3 years. Officially, these have all been voluntary resignations, but the terms and the timing would suggest otherwise.
Biotronik keeps shrinking and it’s obvious why… no new CRM devices anywhere on the horizon, a line of coronary and PVI products that hasn’t gained any traction in the US... and now, no neuro revenue for at least another 24 months (if ever).
With 2023 shaping up to be a bloodbath for hospitals financially as government COVID relief ends, it’s hard to image the situation improving. It’s difficult to get Bio on contract even when customers are flush, now the push to consolidate vendors will grow exponentially.
The big question is how much longer Max will continue to ride the ship down before throwing out a lifeline. I guess it really depends on how much he is willing to lose before admitting the situation is unwinnable.
Biotronik keeps shrinking and it’s obvious why… no new CRM devices anywhere on the horizon, a line of coronary and PVI products that hasn’t gained any traction in the US... and now, no neuro revenue for at least another 24 months (if ever).
With 2023 shaping up to be a bloodbath for hospitals financially as government COVID relief ends, it’s hard to image the situation improving. It’s difficult to get Bio on contract even when customers are flush, now the push to consolidate vendors will grow exponentially.
The big question is how much longer Max will continue to ride the ship down before throwing out a lifeline. I guess it really depends on how much he is willing to lose before admitting the situation is unwinnable.
